[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346535-105":59,"doc-detail-346535-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antitumor-effects-of-santalol-on-non-small-cell-lung-cancer-via-disruption-of-nf-b-mediated-lipid-metabolism-research-paper","Antitumor effects of Santalol on non-small cell lung cancer via disruption of NF-κB-mediated lipid metabolism - Research Paper","","Non-small cell lung cancer (NSCLC) remains difficult to treat, driving demand for new, mechanism-informed therapies. This study evaluates Santalol, a natural compound, for antitumor activity in NSCLC using cell-based assays on A549 and PC9 cells, combining proliferation, cell-cycle, apoptosis, migration, invasion, EMT marker changes, transcriptomics, and lipid- and NF-κB signaling readouts. In vivo testing in an A549 xenograft mouse model assesses tumor suppression and systemic safety. Results show dose-dependent growth inhibition, G1 arrest, apoptosis, reduced invasion and migration, decreased FASN activity and free fatty acids, suppressed NF-κB phosphorylation, and reduced Ki67 without observable systemic toxicity, supporting Santalol as a promising NSCLC candidate.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antitumor-effects-of-santalol-on-non-small-cell-lung-cancer-via-disruption-of-nf-b-mediated-lipid-metabolism-research-paper/346535/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antitumor-effects-of-santalol-on-non-small-cell-lung-cancer-via-disruption-of-nf-b-mediated-lipid-metabolism-research-paper/346535.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this study on Santalol in NSCLC?","Question",{"text":112,"@type":113},"To assess Santalol’s antitumor potential in NSCLC and to clarify the underlying molecular mechanisms, emphasizing lipid metabolism and NF-κB signaling.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was Santalol’s antitumor effect evaluated in vitro?",{"text":117,"@type":113},"Through NSCLC cell line experiments (A549 and PC9) measuring proliferation, cell cycle arrest, apoptosis, migration and invasion, and EMT marker expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What key molecular pathway changes were observed with Santalol treatment?",{"text":121,"@type":113},"Santalol altered genes linked to lipid metabolism and the NF-κB pathway, reduced FASN activity and intracellular free fatty acids, and inhibited NF-κB phosphorylation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346535,1792757281,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Meng et al. Journal of Translational Medicine (2026) 24:292  \n[https://doi.org/10.1186/s12967-025-07670-1](https://doi.org/10.1186/s12967-025-07670-1)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nAntitumor effects of Santalol on non-small cell lung cancer via disruption of NF-κB-mediated lipid metabolism  \nJiaqi Meng1†, Yinxiang Wu1†, Xiaoyuan Bu 1†, Lu Li 1* and Jiquan Chen1*  \nAbstract  \nBackground Non-small cell lung cancer (NSCLC) poses significant therapeutic challenges, highlighting the urgent need for novel and effective therapeutic strategies.  \nPurpose This study aimed to investigate the antitumor potential of Santalol, a natural compound, in NSCLC and to explore its underlying molecular mechanisms, with a particular focus on lipid metabolism and NF-κB signaling. Methods The anti-tumor effects of Santalol were assessed in vitro using NSCLC cell lines (A549, PC9) via proliferation, cell cycle, apoptosis, migration, and invasion assays, along with EMT marker expression. Transcriptomic analysis (RNA sequencing) and functional assays (lipid metabolism, NF-κB phosphorylation) were used to explore molecular mechanisms. In vivo efficacy was evaluated using an A549 xenograft mouse model.  \nResults Santalol dose-dependently inhibited NSCLC cell proliferation, induced G1 phase cell cycle arrest and apoptosis, and significantly suppressed migration, invasion, and modulated EMT markers. Transcriptomic and functional analyses revealed that Santalol altered genes associated with lipid metabolism and the NF-κB pathway. Specifically, Santalol reduced fatty acid synthase (FASN) activity, decreased intracellular free fatty acid levels, and inhibited NF-κB phosphorylation. In vivo, Santalol markedly suppressed tumor growth and reduced Ki67 expression without observable systemic toxicity.  \nConclusion Santalol exerts robust anti-NSCLC effects by inhibiting proliferation, migration, and invasion. These effects are mechanistically associated with the modulation of lipid metabolism and the suppression of the NF-κB signaling cascade. Santalol represents a promising therapeutic candidate for NSCLC.  \nKeywords Santalol, Non-small cell lung cancer (NSCLC), Lipid metabolism, NF-κB signaling, Antitumor activity  \n†Jiaqi Meng, Yinxiang Wu and Xiaoyuan Bu contributed equally to this work.  \n*Correspondence:  \nLu Li [15921225631@163.com](15921225631@163.com)[ ](15921225631@163.com)Jiquan Chen[chenjq9932@163.com](chenjq9932@163.com)  \n1Department of Pulmonary and Critical Care Medicine, Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nMeng et al. Journal of Translational Medicine (2026) 24:292  \nIntroduction  \nLung cancer is a predominant global malignancy and the principal driver of cancer-related deaths worldwide. Annually, this disease causes approximately 1.8 million fatalitie","cbCairyGMhFqPqe7","https://ap.wps.com/l/cbCairyGMhFqPqe7","pdf",10852198,16,"English","# Abstract\n# Introduction\n# Results\n# Conclusion","[{\"question\":\"What is the purpose of this study on Santalol in NSCLC?\",\"answer\":\"To assess Santalol’s antitumor potential in NSCLC and to clarify the underlying molecular mechanisms, emphasizing lipid metabolism and NF-κB signaling.\"},{\"question\":\"How was Santalol’s antitumor effect evaluated in vitro?\",\"answer\":\"Through NSCLC cell line experiments (A549 and PC9) measuring proliferation, cell cycle arrest, apoptosis, migration and invasion, and EMT marker expression.\"},{\"question\":\"What key molecular pathway changes were observed with Santalol treatment?\",\"answer\":\"Santalol altered genes linked to lipid metabolism and the NF-κB pathway, reduced FASN activity and intracellular free fatty acids, and inhibited NF-κB phosphorylation.\"}]","Antitumor effects of Santalol on non-small cell lung cancer via disruption of NF-κB-mediated lipid metabolism - Research Paper | PDF",1790061876,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/774e97f4c184fdbf61904be277bb9530.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73a4ef6a150220139da3811629d4497d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb1d672e1257958f3ab7622da7e1cbae.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/515d2c1f9d78399ae5d91425a239837d.webp",980,1306]